Large Inflow of Money Witnessed in Pfizer

Pfizer (PFE) : Pfizer (PFE) had a healthy money flow of $38.74 million into the stock during the Thursdays trading session. The value of bullish trades on upticks was $109.87 million, whereas, investors only sold shares worth $71.13 million on downticks. The stock closed the day with an up-down ratio of 1.54.The money flow in the block trades to the tune of $42.37 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $50.15 million worth of transactions were on upticks. A paltry $7.79 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 6.44. Pfizer (PFE) stock slid $0.09 intraday and traded at 35.77, a change of -0.25% over previous days close. However, for the week, the company shares are 0.56% compared to previous weeks close.


Pfizer (PFE) : Currently there are 13 street experts covering Pfizer (PFE) stock. The most bullish and bearish price target for the stock is $54 and $33 respectively for the short term. The average price target of all the analysts comes to $38.92. The estimated standard deviation from the target is $5.56. The stock has recorded a 20-day Moving Average of 2.59% and the 50-Day Moving Average is 4.8%.

Pfizer (NYSE:PFE): The stock opened at $35.79 on Thursday but the bulls could not build on the opening and the stock topped out at $35.93 for the day. The stock traded down to $35.56 during the day, due to lack of any buying support eventually closed down at $35.77 with a loss of -0.25% for the day. The stock had closed at $35.86 on the previous day. The total traded volume was 18,103,472 shares.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.